Michelle Lin, PhD

Senior scientist at CRISPR Therapeutics








Michelle Lin received her PhD degree in Pharmacology at Yale University, where she helped design and characterize small cell-permeable peptides to target and reduce tumor vascular hyperpermeability as a therapeutic approach in reducing tumor growth. She later trained at Boston Children’s Hospital in zebrafish developmental hematopoiesis where she studied factors that contribute to hematopoietic stem cell expansion. She joined CRISPR Therapeutics in 2015 and currently leads the program in treating hemoglobinopathies.